Procore Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 19, 2025, reports on a significant leadership transition at Procore Technologies, Inc. The filing details the appointment of Dr. Ajei S. Gopal as Chief Executive Officer Designate and a new member of the Board of Directors, effective September 22, 2025. The Board size was increased from nine to ten directors to accommodate this appointment.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, or debt levels. The document focuses exclusively on executive compensation and governance changes. However, it discloses the following compensation-related financial figures for the new CEO:
- Annual Base Salary: $750,000.
- Target Bonus: 150% of base salary (up to 200% based on performance).
- Sign-on Bonus: $320,000 (one-time).
- Attorney Fee Reimbursement: Up to $125,000.
- Restricted Stock Units (RSUs): Target value of $27.5 million.
- Performance Stock Units (PSUs): Target value of $27.5 million, tied to Total Shareholder Return (TSR) relative to the S&P Completion Index Information Technology.
Material Changes Versus Prior Period
The primary material change is the succession planning for the Chief Executive Officer role. Tooey Courtemanche, the founder and current CEO, will continue to serve as President and CEO until the first Monday following the public announcement of financial results for the fiscal quarter ending September 30, 2025. Dr. Gopal will assume the role of President and CEO on that date. Courtemanche will remain Chair of the Board.
Guidance, Outlook, and Management Commentary
In a press release issued concurrently with this filing, the Company reaffirmed its third-quarter and full-year fiscal 2025 guidance, which was previously announced on July 31, 2025. The filing notes that Dr. Gopal was selected for his extensive experience in the technology and software industries, including his tenure as CEO of Ansys, Inc. until its acquisition by Synopsys, Inc. in July 2025.
Severance and Contingencies: The filing outlines significant severance protections for Dr. Gopal:
- Termination without Cause/Good Reason: 18 months of base salary and target bonus, plus 18 months of COBRA premiums and accelerated equity vesting.
- Change in Control (CIC) Termination: 24 months of base salary and target bonus, plus 24 months of COBRA premiums and full accelerated equity vesting.
- Succession Plan Resignation: 18 months of base salary and target bonus, plus continued vesting of equity awards granted more than six months prior.
Investor Verification Checklist
- Verify the exact date of the Q3 2025 earnings release to determine the precise "CEO Start Date" for Dr. Gopal.
- Review the attached Exhibit 10.1 (Offer Letter) and Exhibit 10.2 (Severance Agreement) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the 30-Day Volume-Weighted Average Price (VWAP) used to calculate the actual number of RSUs and PSUs granted.
- Monitor the transition period to ensure continuity of operations between the current CEO and the incoming CEO.
- Assess the impact of the increased Board size and new director composition on corporate governance.